Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

488 results about "Lactone Compound" patented technology

Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring (IUPAC).

Method for Treatment of Inflammatory Disorders Using Triptolide Compounds

InactiveUS20070244080A1Inhibiting cytokine productionRelieve symptomsOrganic active ingredientsAntipyreticHepatic fibrosisTriptolide
Inflammatory disorders, including obliterative airway disease, renal fibrosis, diabetic nephropathy, and liver fibrosis are treated with immunosuppressive triptolide compounds, in particular triptolide compounds effective to inhibit TGF-β production in a patient afflicted with such a disorder.
Owner:PHARMAGENESIS

Toner, and developer and image forming apparatus using the toner

A toner, including a lactone compound having not less than 14-membered rings; and a resin including a crystalline polyester unit.
Owner:RICOH KK

Method for preparing tylosin macrolide and derivatives thereof

The invention relates to a method for preparing tylosin macrolide and derivatives thereof. The method for preparing the tylosin macrolide and derivatives thereof comprises the following steps: in the presence of a fatty hydrocarbon polar solvent or aromatic hydrocarbon solvent, mixing tylosin A or salt of tylosin A and a piperidyl compound I with formic acid or aqueous solution of formic acid, so as to generate a 20-piperidyl-tylosin compound; then mixing and stirring with HCOOH or aqueous solution of HCOOH, so as to generate a 23-O-(6-deoxidation-2,3-bis-O-methyl-D-allose)-20-piperidyl-5-O-mycaminose-tylosin lactone compound; then reacting with an inorganic acid for 3-8 hours to form a 23-hydroxyl-20-piperidyl-5-O-mycaminose-tylosin lactone compound; then oxidizing to obtain an active compound by adopting a selective combined oxidizer system; reacting the active compound with a piperidyl compound II and formic acid or aqueous solution of formic acid, thus obtaining a tylosin macrolide and derivative of the tylosin macrolide. In the preparation process of the compounds, application amount of inorganic acid is reduced to 25-36 mol equivalent weight, less byproducts and high-concentration waste water are produced, and yield is increased.
Owner:烟台万润药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products